Cannabinoid Receptor Inhibitors

CB1

CB2

Cannabinoid Receptor Ligands, Inhibitors, Agonists, Antagonists, Activators & Modulators

Product Name	CB1	CB2	Purity
Anandamide	CB1	CB2	≥99.0%
Rimonabant	CB1 , Ki: 1.8 nM		99.52%
Pregnenolone	CB1		99.87%
BMS-812204	CB1
SR144528		CB2	99.02%
Rimonabant Hydrochloride	CB1 , Ki: 1.8 nM		99.79%
JD-5037	CB1 , IC₅₀: 1.5 nM		99.38%
Pregnenolone monosulfate sodium	CB1		99.96%
Synaptamide	CB1 , Ki: 633 nM	CB2 , Ki: 3843 nM	99.30%
N-Oleoyl glycine	CB1		99.0%
Yangonin	CB1 , IC₅₀: 1.79 μM CB1 , Ki: 0.72 μM		99.65%
Pregnenolone monosulfate	CB1		99.96%
GW-405833	CB1 , EC₅₀: 16.1 μM	CB2 , EC₅₀: 50.7 nM	98.91%
Leelamine	CB1	CB2	98.36%
Tetrahydromagnolol	CB1 , EC₅₀: 9010 nM CB1 , Ki: 2260 nM	CB2 , EC₅₀: 170 nM CB2 , Ki: 416 nM	99.89%
Leelamine hydrochloride	CB1		98.10%
Pregnenolone (Standard)	CB1
AM281	CB1 , IC₅₀: 9.91 nM	CB2 , IC₅₀: 13000 nM	≥99.0%
GW405833 hydrochloride	CB1 , IC₅₀: 16.1 μM	CB2 , IC₅₀: 50.7 nM	99.59%
Etrinabdione		CB2	99.16%
CB2R PAM		cannabinoid type-2 receptors	98.09%
CB1/2 agonist 1	hCB1-R, EC₅₀: 56.15 nM	cannabinoid type-2 receptors, EC₅₀: 11.63 nM	98.68%
CB1 antagonist 4	CB1		98.00%
N-Arachidonyldopamine	CB1 , Ki: 250 nM		98.36%
Drinabant	rCB1-R, IC₅₀: 10 nM hCB1-R, IC₅₀: 25 nM	CB2 , IC₅₀: 10000 nM	99.0%
Ibipinabant	CB1 , Ki: 7.8 nM	CB2 , Ki: 7943 nM	99.90%
SCH 336		hCB2-R	98.63%
Bay 59-3074	CB1 , Ki: 48.3 nM	CB2 , Ki: 45.5 nM	98.60%
CB1/2 agonist 3	hCB1-R, Ki: 5.9 nM	hCB2-R, Ki: 3.5 nM	99.27%
AZD1940	hCB1-R, pKi: 7.93	hCB2-R, pKi: 9.06	99.58%
Vicasinabin		hCB2-R, EC₅₀: 2.81 nM	98.37%
CB2R antagonist 3		CB2R	98.08%
(R)-Methanandamide	CB1 , Ki: 20 nM		99.61%
GW 833972A		hCB2-R, pEC₅₀: 7.3 rat CB2-R, pEC₅₀: 7.5	99.91%
CB1 inverse agonist 2	CB1 , pKi: 9.7	CB2 , pKi: 6.0	99.15%
Zevaquenabant	CB1		99.64%
2-Palmitoylglycerol	CB1		99.0%
Dihomo-γ-Linolenoyl Ethanolamide	hCB1-R, Ki: 857 nM	hCB2-R, Ki: 598 nM	99.9%
Auriculasin	CB1 , IC₅₀: 8.92 μM		98.58%
PGN36		cannabinoid type-2 receptors, Ki: 0.09 μM	99.74%
ANEB-001	CB1		99.73%
RVD-Hpα TFA	CB1		99.32%
URB447	CB1 , IC₅₀: 313 nM		99.5%
MJ15	rCB1-R, IC₅₀: 118.9 pM rCB1-R, Ki: 27.2 pM		99.78%
CB2 modulator 1		CB2	99.75%
CB2 receptor agonist 2		CB2 , Ki: 8.5 nM	99.0%
Eicosapentaenoyl ethanolamide	CB1	CB2	98.38%
Tedalinab		CB2	99.94%
PSNCBAM-1	hCB1-R, EC₅₀: 0.1 μM		99.48%
GAT211	CB1		99.98%
Noladin ether	CB1 , Ki: 21.2 nM	CB2 , Ki: >3 mM	≥98.0%
L759633	CB1 , Ki: 1043 nM	CB2 , Ki: 6.4 nM	≥99.0%
Nonabine	CB1		99.95%
CB2R/FAAH modulator-3	CB1 , Ki: 67.6 nM	CB2 , Ki: 20.1 nM	99.71%
PSB-SB-1203	CB1 , Ki: 0.244 μM	CB2 , Ki: 0.21 μM
BNS808	CB1R, IC₅₀: 0.8 nM
CB1-IN-2	CB1 , IC₅₀: 0.644 μM
CBR Agonist-2	hCB1-R, EC₅₀: 960 nM hCB1-R, Ki: 970 nM
hBChE-IN-2		hCB2-R, IC₅₀: 0.78 μM
CB2R/FAAH modulator-2	CB1 , Ki: 152.9 nM	CB2 , Ki: 10.8 nM
RTICBM-189	mCB₁, pIC₅₀: 6.25 hCB₁, pIC₅₀: 5.29 CB1 , pIC₅₀: 7.54		99.73%
CB1/2 receptor-1	CB1	CB2
Amauromine	CB1 , Kb: 66.6 nM CB1 , Ki: 178 nM
AB-FUBICA	CB1 , EC₅₀: 21 nM	CB2 , EC₅₀: 15 nM
PM226		CB2 , EC₅₀: 39 nM CB2 , Ki: 13 nM
CB1R Allosteric modulator 1	hCB1-R
CB2R agonist 4		CB2R, EC₅₀: 6.9 μM
L-759656	hCB1-R, Ki: 4888 nM	hCB2-R, Ki: 11.8 nM
AZD-2207	CB1
NIDA-41020	CB1 , Ki: 4.1 nM
MK-5596	CB1 , EC₅₀: 5.8 nM CB1 , IC₅₀: 1.0 nM
rel-O-2050	CB1
CB1/2 agonist 2	hCB1-R, Ki: 3.5 nM	hCB2-R, Ki: 1.2 nM
CB1R agonist 1	CB1R, Ki: 0.95 nM
CB1 antagonist 6	CB1R, IC₅₀: 23 nM
MDA7	rCB1-R, Ki: 2565 nM	hCB2-R, IC₅₀: 128 nM hCB2-R, Ki: 422 nM rat CB2-R, IC₅₀: 67.4 nM rat CB2-R, Ki: 238 nM
TRPV1/CB2 agonist 1		CB2
LY320135	CB1 , Ki: 141 nM	CB2 , Ki: >10 μM
CB2R antagonist 4		CB2R, pKi: 6.54
CB2 receptor agonist 9		CB2R, EC₅₀: 16.2 nM
AChE/BChE-IN-18		CB2 , Ki: 31 nM
RVD-Hpα	CB1
CB1R antagonist 1	hCB1-R, EC₅₀: 10 μM hCB1-R, IC₅₀: 4.2 μM		99.89%
ISAM-CG557		CB2R, Ki: 54.6 nM
UVI3502	CB1 , IC₅₀: 4641 nM	CB2 , IC₅₀: 16200 nM
CB1R Allosteric modulator 3	CB1		98.05%
O-2050	CB1 , Ki: 2.5 nM	CB2 , Ki: 0.2 nM
AM12814	rCB1-R, Ki: 0.7 nM	hCB2-R, Ki: 3.4 nM
Isopropyl dodec-11-enylfluorophosphonate	CB1 , IC₅₀: 2 μM
CB2R agonist 1		CB2R, EC₅₀: 0.56 μM
CB2R/FAAH modulator-1	CB1R, EC₅₀: 489 nM CB1R, Ki: 241.3 nM	CB2R, EC₅₀: 123.6 nM CB2R, Ki: 14.8 nM
TRPM8 antagonist 4		CB2R, EC₅₀: 54.2 nM CB2R, Ki: 3.2 μM
Δ9-THCB	CB1 , Ki: 15 nM	CB2 , Ki: 51 nM
SMM-189		CB2
CB1R Allosteric modulator 4	hCB1-R
Mead ethanolamide	CB1 , Kd: 753 nM	CB2 , Kd: 1810 nM
CB2 receptor agonist 8		CB2R
CB2 receptor agonist 6		CB2R
R-2 Methanandamide	rCB1-R, Ki: 119 nM
MN-25	CB1 , Ki: 254 nM	CB2 , Ki: 11 nM
TRPM8 antagonist 4 prodrug		CB2 , IC₅₀: 51.2 nM
CBR Agonist-1	rCB1-R, Ki: 0.18 μM	hCB2-R, Ki: 1.22 μM
BAY 38-7271	CB1 , Ki: 1.85 nM	CB2 , Ki: 5.96 nM
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide	CB1 , Ki: 21 μM	CB2 , Ki: 21 μM
Neuroprotective agent 15		CB2
(±)5(6)-EET Ethanolamide	hCB1-R, Ki: 11.4 μM	hCB2-R, Ki: 8.9 nM
(R)-SLV 319	CB1 , Ki: 894 nM
AM11638	CB1	CB2
CB1R Allosteric modulator 2	hCB1-R
CB1-IN-3	CB1
CB2R agonist 3		CB2R, EC₅₀: 0.37 μM
CB2R probe 1		cannabinoid type-2 receptors, Ki: 130 nM
TM38837	CB1
AM11542	CB1 , Ki: 0.11 nM
Δ8-THC methyl ether		CB2
Δ8-THCP	CB1
MRL-650	CB1 , IC₅₀: 7.5 nM	CB2 , IC₅₀: 4100 nM
PF-03550096		CB2 , Ki: 7.9 nM
PSB-SB1202	CB1 , EC₅₀: 56 nM CB1 , Ki: 32 nM	CB2 , EC₅₀: 14 nM CB2 , Ki: 49 nM	99.48%
Tocrifluor 1117	CB1
CB1 antagonist 5	hCB₁, EC₅₀: 195 nM hCB₁, Ki: 243 nM
AM9405	CB1 , IC₅₀: 45.71 nM
Docosatetraenylethanolamide	CB1
CB2R-IN-1		CB2 , Ki: 0.9 nM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4